BR112023018368A2 - Composições e métodos para tratar anemia associada a um transtorno ribossômico - Google Patents
Composições e métodos para tratar anemia associada a um transtorno ribossômicoInfo
- Publication number
- BR112023018368A2 BR112023018368A2 BR112023018368A BR112023018368A BR112023018368A2 BR 112023018368 A2 BR112023018368 A2 BR 112023018368A2 BR 112023018368 A BR112023018368 A BR 112023018368A BR 112023018368 A BR112023018368 A BR 112023018368A BR 112023018368 A2 BR112023018368 A2 BR 112023018368A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- compositions
- anemia associated
- disorder
- ribosomic
- Prior art date
Links
- 208000007502 anemia Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- 210000003705 ribosome Anatomy 0.000 abstract 2
- 102000010726 Glycine Plasma Membrane Transport Proteins Human genes 0.000 abstract 1
- 108010063380 Glycine Plasma Membrane Transport Proteins Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
composições e métodos para tratar anemia associada a um transtorno ribossômico. as presentes modalidades são dirigidas a métodos de utilização de inibidores do transportador de glicina, tais como inibidores de glyt1, ou sais, solvatos ou prófármacos farmaceuticamente aceitáveis dos mesmos, ou composições farmacêuticas dos mesmos, para prevenir ou tratar anemia associada a um transtorno ribossômico, e síndromes relacionadas dos mesmos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163160413P | 2021-03-12 | 2021-03-12 | |
| US202163185466P | 2021-05-07 | 2021-05-07 | |
| PCT/US2022/020039 WO2022192731A1 (en) | 2021-03-12 | 2022-03-11 | Compositions and methods for treating anemia associated with a ribosomal disorder |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023018368A2 true BR112023018368A2 (pt) | 2023-10-31 |
Family
ID=83228389
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023018368A BR112023018368A2 (pt) | 2021-03-12 | 2022-03-11 | Composições e métodos para tratar anemia associada a um transtorno ribossômico |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP4304597A1 (pt) |
| JP (1) | JP2024509267A (pt) |
| KR (1) | KR20230169982A (pt) |
| AU (1) | AU2022232452A1 (pt) |
| BR (1) | BR112023018368A2 (pt) |
| CA (1) | CA3213396A1 (pt) |
| IL (1) | IL305803A (pt) |
| MX (1) | MX2023010477A (pt) |
| WO (1) | WO2022192731A1 (pt) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3137073T1 (sl) * | 2014-04-30 | 2018-09-28 | F. Hoffmann-La Roche Ag | Zaviralci prenašalca GlyT1 za uporabo pri zdravljenju hematoloških bolezni |
| CN116212025A (zh) * | 2020-01-09 | 2023-06-06 | 迪斯克医药公司 | 治疗红细胞生成性原卟啉病、x连锁原卟啉病或先天性红细胞生成性卟啉病的方法 |
-
2022
- 2022-03-11 BR BR112023018368A patent/BR112023018368A2/pt unknown
- 2022-03-11 KR KR1020237034673A patent/KR20230169982A/ko unknown
- 2022-03-11 CA CA3213396A patent/CA3213396A1/en active Pending
- 2022-03-11 WO PCT/US2022/020039 patent/WO2022192731A1/en active Application Filing
- 2022-03-11 EP EP22768133.5A patent/EP4304597A1/en active Pending
- 2022-03-11 JP JP2023555277A patent/JP2024509267A/ja active Pending
- 2022-03-11 IL IL305803A patent/IL305803A/en unknown
- 2022-03-11 MX MX2023010477A patent/MX2023010477A/es unknown
- 2022-03-11 AU AU2022232452A patent/AU2022232452A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024509267A (ja) | 2024-02-29 |
| EP4304597A1 (en) | 2024-01-17 |
| CA3213396A1 (en) | 2022-09-15 |
| IL305803A (en) | 2023-11-01 |
| AU2022232452A1 (en) | 2023-10-26 |
| WO2022192731A1 (en) | 2022-09-15 |
| MX2023010477A (es) | 2023-11-09 |
| KR20230169982A (ko) | 2023-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022017393A2 (pt) | Composto, composição farmacêutica, método para tratar um transtorno mediado por brd9, e, uso de um composto | |
| CY1124483T1 (el) | Συνθεσεις και μεθοδοι για την αναστολη της δραστικοτητας της αργινασης | |
| CY1123557T1 (el) | Συνθεσεις και μεθοδοι για την αναστολη της δραστηριοτητας της αργινασης | |
| BR112021022504A2 (pt) | Inibidores de autofagia de fenilaminopirimidina amida e métodos de uso dos mesmos | |
| MX2022002938A (es) | Compuestos inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) cooperativos para metiltioadenosina (mta). | |
| BR112021022576A2 (pt) | Inibidores de autofagia de heteroarilaminopirimidina amida e métodos de uso dos mesmos | |
| BR112021023359A2 (pt) | Inibidores de g12c de kras e usos dos mesmos | |
| MX2019001849A (es) | Inhibidores de cdk2/4/6 de piridopirimidinona. | |
| BR112017024331A2 (pt) | composto, composição farmacêutica, método de tratamento de um humano, métodos para inibir a atividade de uma proteína ido1, o crescimento ou a proliferação de células cancerosas, e a imunossupressão em um paciente, e de tratamento de uma doença, e, uso de um composto | |
| BR112018068565A2 (pt) | combinações de inibidores de lsd1 para uso no tratamento de tumores sólidos | |
| BR112018013251A2 (pt) | compostos heterocílicos tricíclicos fundidos como inibidores da hiv integrase | |
| BR112017019779A2 (pt) | composto, e, composição farmacêutica | |
| BR112016003201A2 (pt) | inibidores de grp94 seletivos e usos dos mesmos | |
| BR112021020285A2 (pt) | Métodos e composições para degradação de proteína alvejada | |
| BR112019004248A2 (pt) | inibidores da dopamina-b-hidroxilase | |
| BR112018070123A2 (pt) | oxiesterós e métodos de uso dos mesmos | |
| BR112021017350A2 (pt) | Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp | |
| BR112021017772A2 (pt) | Bloqueadores de canais de íons carregados e métodos para uso | |
| EA202091640A1 (ru) | Способы лечения опосредованного il-6 воспаления без иммунодепрессии | |
| BR112018070536A2 (pt) | composto, composição farmacêutica, combinação, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de uma doença ou condição | |
| BR112022018067A2 (pt) | Aminas de pirrolopirimidina como inibidores de complemento | |
| BR112021025544A2 (pt) | Inibidores de autofagia de aminopirimidina amida e métodos de uso dos mesmos | |
| TR201902686T4 (tr) | Aurora A kinaz inhibitörü. | |
| CL2021001739A1 (es) | Inhibidores de la proteína de activación de fibroblastos. | |
| BR112017018198A2 (pt) | inibição da atividade de olig2 |